Table 1: Mesoglycan in ischemic stroke. Clinical studies.

AuthorStudy designPathologyPatients ( )Doses/routeResults

Orefice [12]ProspectiveStroke
(1–3 mo before)
30Mesoglycan 50 mg twice daily orally for 3 monthsMesoglycan: safe and effective in reducing FBR without interfering with other coagulative parameters
Orefice [11]Randomized ControlledStroke
(2-3 mo before)
46Mesoglycan 50 mg twice daily orally versus Ticlopidine 250 mg twice daily, for 2 monthsMesoglycan and ticlopidine: both safe and effective in reducing FBR without interfering with other coagulative parameters
Vecchio [13]ProspectiveStroke
(within 2 mo)
20Mesoglycan 30 mg twice daily intramuscular, for 15 daysMesoglycan: significant reduction in FBR, cholesterol, triglycerides, improved erythrocyte filterability without interfering with other coagulative parameters
Mansi [14]ProspectiveTIA or stroke (within 3 mo)30Mesoglycan 50 mg twice daily orallyMesoglycan decreases neurologic deficits
Forconi [15]Multicenter clinical trialHistory of stroke, TIA, RIND or minor stroke1,398Mesoglycan 30 mg twice daily i.m., then 100 mg daily orally, versus ASA 300 mg dailyNo differences. ASA: higher incidence of side effects